Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Currently, there is no approved treatment for COVID-19 in France, either for the acute phase,
nor for the late chronic phase. the investigator suggest that nintedanib has the potential to
block the development of lung fibrosis when initiated early enough to inhibit the activation
of mesenchymal cells and the progression of virus-induced pulmonary fibrosis. Computerized
Tomography (CT) manifestations of fibrosis or fibrous stripes are described in COVID-19 (Ye,
Eur Radiol 2020). Pan et al observed fibrous stripes in 17% patients in the early phase of
the disease (Pan, Eur Radiol 2020). Ye et al observed bronchiectasis in 2 patients (15.4%)
and evidence of pulmonary fibrosis in 3 patients (23.7%) at HRCT performed at 4 weeks (Ye,
Eur Radiol 2020). Long term data are still lacking in patients with COVID-19 and the
investigators do not know how many patients will have fibrotic sequelae from the acute
illness.